NDAORALTABLET
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
YONSA (abiraterone acetate) by Fosun Pharma is abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/c17,20-lyase (cyp17). First approved in 2018.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YONSA (abiraterone acetate) is an oral androgen biosynthesis inhibitor that blocks CYP17, an enzyme required for testosterone and other androgen production in testicular, adrenal, and prostatic tissues. It is indicated for men with castration-resistant prostate cancer (CRPC) to reduce serum androgens and slow disease progression. The drug works by inhibiting a critical step in androgen synthesis, offering an alternative mechanism to standard androgen deprivation therapy.
$0.014BPart D
Peak7.7 years to LOEProduct is at peak lifecycle with $14M in Part D spending and ~1,344 claims annually; team size likely stable with mature promotional infrastructure.
Mechanism of Action
abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. CYP17 catalyzes two sequential reactions: 1) the conversion of pregnenolone…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Started Aug 2026
600 enrolled
Metastatic Castration Resistant Prostate Cancer
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
Started May 2026
126 enrolled
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
Started Oct 2025
0Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Deleterious HRR Gene MutationBRCA1 Gene Mutation+7 more
Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer
Started Apr 2025
0Prostate CancerCastrate Resistant Prostate CancerHomologous Recombination Deficiency
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Started Jan 2025
72 enrolled
Recurrent Prostate CarcinomaStage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8
Worked on YONSA at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.